Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study
- 1Panaxea 's-Hertogenbosch The Netherlands
- 2Department Bio-adaptive Production Fraunhofer Institute for Production Technology IPT Aachen, North Rhine-Westphalia Germany
- 3Faculty of Health, Medicine and Life Sciences Maastricht University Maatricht, Limburg The Netherlands
Abstract
Background: Although effective, current chimeric antigen receptor T-cell (CAR-T) production methods—centralized, manual, and complex—are cost-intensive, time-consuming, and prone to variability. AIDPATH (AI-Powered Decentralized Production for Advanced Therapies in the Hospital) proposes a decentralized, automated alternative that integrates patient-specific data; optimizes resource use; and potentially improves cell viability, manufacturing efficiency, and patient outcomes.
Objective: The aim of this study was to compare CAR-T therapy produced by the AIDPATH platform to both ciltacabtagene autoleucel (cilta-cel) and standard of care (SoC) for patients with triple-class refractory multiple myeloma (MM) over a 40-year time horizon from the hospital perspective in Germany.
Methods: A partitioned survival model reflecting 3 health states (progression-free disease, progressed disease, and death) was used. The analysis used clinical trial data for cilta-cel, real-world data for SoC, and estimated parameters for AIDPATH due to the developmental status of the platform. The primary outcome was the incremental cost-effectiveness ratio; secondary outcomes included sensitivity and scenario analyses.
Results: On the basis of the model used in this analysis, AIDPATH was dominant compared to both cilta-cel and SoC. Most costs for CAR-T therapies were driven by acquisition and adverse events. Sensitivity analyses showed that the results were most influenced by discount rates and assumptions about progression-free survival. Scenario analyses, including reduced adverse events and shorter vein-to-vein times for AIDPATH, further supported its cost-effectiveness.
Conclusions: This is the first study to assess the cost-effectiveness of a CAR-T product generated with AI support in Germany from the hospital perspective. AIDPATH was found to be a cost-effective alternative to both cilta-cel and SoC, making it a promising option for future implementation. Although further data are needed, this study provides valuable guidance for health care stakeholders, reimbursement discussions, and future research.
Related
- Technology-Enriched High-Fidelity Simulation in Nursing Education: Learning Effectiveness and Mediating Model.
- Effectiveness and user experience of ambient artificial intelligence-driven scribe technology among clinicians: a protocol for a systematic review.
- Technology Demonstration of a Portable Sensorimotor Assessment System after Short-Duration Spaceflight
- Three pillars for digital health assessment in LMICs: a mini review of technology benchmarking, digital health literacy, and social media listening
- Cost-effectiveness of disitamab vedotin plus toripalimab versus chemotherapy alone as first-line treatment for HER2-overexpressing advanced urothelial carcinoma: a cost-effectiveness analysis from the Chinese healthcare system perspective
BibTeX
@article{boot2026costeffectiveness,
title = {{Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study}},
author = {Iris W A Boot and Anna Louisa Weltin and Ysanne de Graaf and Hubertus J M Vrijhoef},
journal = {JMIR Cancer},
year = {2026},
month = oct,
doi = {10.2196/92253},
url = {https://doi.org/10.2196/92253},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study
AU - Iris W A Boot
AU - Anna Louisa Weltin
AU - Ysanne de Graaf
AU - Hubertus J M Vrijhoef
PY - 2026
DA - 2026/10/13
JO - JMIR Cancer
DO - 10.2196/92253
UR - https://doi.org/10.2196/92253
AB - Background: Although effective, current chimeric antigen receptor T-cell (CAR-T) production methods—centralized, manual, and complex—are cost-intensive, time-consuming, and prone to variability. AIDPATH (AI-Powered Decentralized Production for Advanced Therapies in the Hospital) proposes a decentralized, automated alternative that integrates patient-specific data; optimizes resource use; and potentially improves cell viability, manufacturing efficiency, and patient outcomes. Objective: The aim of this study was to compare CAR-T therapy produced by the AIDPATH platform to both ciltacabtagene autoleucel (cilta-cel) and standard of care (SoC) for patients with triple-class refractory multiple myeloma (MM) over a 40-year time horizon from the hospital perspective in Germany. Methods: A partitioned survival model reflecting 3 health states (progression-free disease, progressed disease, and death) was used. The analysis used clinical trial data for cilta-cel, real-world data for SoC, and estimated parameters for AIDPATH due to the developmental status of the platform. The primary outcome was the incremental cost-effectiveness ratio; secondary outcomes included sensitivity and scenario analyses. Results: On the basis of the model used in this analysis, AIDPATH was dominant compared to both cilta-cel and SoC. Most costs for CAR-T therapies were driven by acquisition and adverse events. Sensitivity analyses showed that the results were most influenced by discount rates and assumptions about progression-free survival. Scenario analyses, including reduced adverse events and shorter vein-to-vein times for AIDPATH, further supported its cost-effectiveness. Conclusions: This is the first study to assess the cost-effectiveness of a CAR-T product generated with AI support in Germany from the hospital perspective. AIDPATH was found to be a cost-effective alternative to both cilta-cel and SoC, making it a promising option for future implementation. Although further data are needed, this study provides valuable guidance for health care stakeholders, reimbursement discussions, and future research.
SN - 2369-1999
ER -